221 related articles for article (PubMed ID: 19621084)
1. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.
Palaninathan SK; Mohamedmohaideen NN; Orlandini E; Ortore G; Nencetti S; Lapucci A; Rossello A; Freundlich JS; Sacchettini JC
PLoS One; 2009 Jul; 4(7):e6290. PubMed ID: 19621084
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
3. Kinetic stabilization of an oligomeric protein by a single ligand binding event.
Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW
J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192
[TBL] [Abstract][Full Text] [Related]
4. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.
Adamski-Werner SL; Palaninathan SK; Sacchettini JC; Kelly JW
J Med Chem; 2004 Jan; 47(2):355-74. PubMed ID: 14711308
[TBL] [Abstract][Full Text] [Related]
5. Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
Yokoyama T; Mizuguchi M
J Med Chem; 2019 Feb; 62(4):2076-2082. PubMed ID: 30688456
[TBL] [Abstract][Full Text] [Related]
6. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.
Guo X; Liu Z; Zheng Y; Li Y; Li L; Liu H; Chen Z; Wu L
Drug Des Devel Ther; 2020; 14():1057-1081. PubMed ID: 32210536
[TBL] [Abstract][Full Text] [Related]
7. X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors.
Ciccone L; Nencetti S; Rossello A; Tepshi L; Stura EA; Orlandini E
J Enzyme Inhib Med Chem; 2016 Oct; 31(5):824-33. PubMed ID: 26235916
[TBL] [Abstract][Full Text] [Related]
8. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
Ciccone L; Nencetti S; Rossello A; Stura EA; Orlandini E
J Enzyme Inhib Med Chem; 2016; 31(sup1):40-51. PubMed ID: 27067161
[TBL] [Abstract][Full Text] [Related]
10. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
[TBL] [Abstract][Full Text] [Related]
11. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
[TBL] [Abstract][Full Text] [Related]
12. Monoaryl derivatives as transthyretin fibril formation inhibitors: Design, synthesis, biological evaluation and structural analysis.
Ciccone L; Nencetti S; Tonali N; Fruchart-Gaillard C; Shepard W; Nuti E; Camodeca C; Rossello A; Orlandini E
Bioorg Med Chem; 2020 Sep; 28(18):115673. PubMed ID: 32828431
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors.
Morais-de-Sá E; Pereira PJ; Saraiva MJ; Damas AM
J Biol Chem; 2004 Dec; 279(51):53483-90. PubMed ID: 15469931
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
Tomar D; Khan T; Singh RR; Mishra S; Gupta S; Surolia A; Salunke DM
PLoS One; 2012; 7(9):e43522. PubMed ID: 22973437
[TBL] [Abstract][Full Text] [Related]
15. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
[TBL] [Abstract][Full Text] [Related]
16. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation.
Johnson SM; Petrassi HM; Palaninathan SK; Mohamedmohaideen NN; Purkey HE; Nichols C; Chiang KP; Walkup T; Sacchettini JC; Sharpless KB; Kelly JW
J Med Chem; 2005 Mar; 48(5):1576-87. PubMed ID: 15743199
[TBL] [Abstract][Full Text] [Related]
17. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
Miller SR; Sekijima Y; Kelly JW
Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
19. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative.
Almeida MR; Macedo B; Cardoso I; Alves I; Valencia G; Arsequell G; Planas A; Saraiva MJ
Biochem J; 2004 Jul; 381(Pt 2):351-6. PubMed ID: 15080795
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors.
Oza VB; Smith C; Raman P; Koepf EK; Lashuel HA; Petrassi HM; Chiang KP; Powers ET; Sachettinni J; Kelly JW
J Med Chem; 2002 Jan; 45(2):321-32. PubMed ID: 11784137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
